RxDoctor Payments Data

Ashley Head

Psychiatric/Mental Health · Benton, ARNPI 1730661570

Payments from drug & device makers

$857in general payments, 2019–2025

Across 40 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$247
  • Neurocrine Biosciences, Inc.$212
  • Alkermes, Inc.$147
  • Otsuka America Pharmaceutical, Inc.$97
  • Teva Pharmaceuticals USA, Inc.$74
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$28
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$76189%
  • Education$9711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$857 in reported general payments places this provider in the 50th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$31,608
Medicare patients
111
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate75$645,957
Austedo XrDeutetrabenazine30$195,408
Invega SustennaPaliperidone Palmitate44$138,620
Abilify MaintenaAripiprazole38$120,511
VraylarCariprazine Hcl29$41,266
UzedyRisperidone24$38,133
RexultiBrexpiprazole17$23,811
VivitrolNaltrexone Microspheres11$19,479
Chlorpromazine Hcl96$17,562
Paliperidone ErPaliperidone66$17,084
Haloperidol Decanoate176$12,719
Aripiprazole242$6,400
Ziprasidone Hcl93$5,647
Benztropine Mesylate372$5,434
Haloperidol170$5,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$212$645,95775 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy, Loxapine$74$234,43876 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$97$144,32255 claims
AbbVieVraylar$19$41,26629 claims
Alkermes, Inc.Vivitrol$147$19,47911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Benton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →